Lumos Diagnostics Holdings (ASX:LDX) Growth Rank : 0 (As of Jun. 19, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Growth Rank?

Lumos Diagnostics Holdings has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Lumos Diagnostics Holdings Growth Rank Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings (ASX:LDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

LDXHF:USA

Address

2724 Loker Ave West, Carlsbad, CA, USA, 92010

Website

https://www.lumosdiagnostics.com

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines